200wk Uptrend — rising+above (sma 56.10 vs px 110)
Funds Accumulating — momZ +1.20 · 7.05→7.50
Seasonal Tailwind — november med 6.3% (mag 2/3) · posClose 63.64% (rel 1/3) · n22 ×0.75 = 4.7
Founder-Led — founder/CEO led
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluid… Read full Trend Edge analysis →
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: March 16, 2004
Headquarters: 12390 El Camino Real, San Diego, CA, United States, 92130
Founder-Led: Yes — Helen Torley (President, Chief Executive Officer and Member of the Board of Directors)
Key Metrics
Current Price
$110.42
Market Cap
$12.47B
Float
112.2M
Shares Outstanding
113.5M
P/E (Forward)
11.45
P/E (TTM)
32.12
Price/Sales (TTM)
7.49
vs. Analyst Target
-7.5% to analyst PT
Profit Margin
24.86%
Operating Margin (TTM)
59.80%
Revenue (TTM)
$1.66B
Earnings Growth (YoY)
42.90%
Dividend Rate
None
Analyst Target Price
$102.11 (9 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$268M
$129M
$224M
$148M
2021
$443M
$403M
$362M
$279M
2022
$660M
$202M
$521M
$316M
2023
$829M
$282M
$637M
$452M
2024
$1.02B
$444M
$856M
$657M
2025
$1.40B
$317M
$1.09B
$573M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Sep 2025
$354M
$175M
Dec 2025
$452M
-$142M
Mar 2026
$377M
$150M
Jun 2026
$481M
$230M
Ownership & Float
Insider Ownership
1.1%
Institutional Ownership
113.1%
Short Float
13.3%
% of All Funds Holding
7.50%
Number of Funds Holding
660
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$107.93
Near-term / short-term trend
Weekly
40-Week SMA
$80.02
Medium-term trend
Weekly
80-Week SMA
$71.87
Cyclical trend (business cycle)
Weekly
200-Week SMA
$56.10
Secular trend (multi-year)
Monthly
10-Month SMA
$82.42
Near-term monthly trend
Monthly
20-Month SMA
$73.39
Medium-term monthly trend
Monthly
40-Month SMA
$59.72
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$83.00
support
1.22x
1 months ago
$60.00
support
1.16x
13 months ago
Historical Earnings Reactions (91 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.67%
0.35%
52.75%
17.55%
-12.37%
1 Day
0.36%
0.54%
51.65%
25.73%
-24.74%
1 Week
2.68%
0.62%
52.75%
60.43%
-20.86%
2 Weeks
1.88%
-0.21%
48.35%
43.59%
-28.05%
1 Month
4.47%
-0.11%
48.35%
173.26%
-26.83%
Next earnings: November 2, 2026 (21 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
-0.5%
50.0%
22
Feb
2.3%
59.1%
22
Mar
3.8%
50.0%
22
Apr
-0.7%
56.5%
23
May
0.7%
56.5%
23
Jun
5.0%
60.9%
23
Jul
3.6%
65.2%
23
Aug
0.7%
52.2%
23
Sep
2.1%
39.1%
23
Oct
-2.7%
45.5%
22
Nov
6.5%
63.6%
22
Dec
11.0%
54.5%
22
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
-0.16%
46.6%
1063
Tuesday
0.20%
50.6%
1165
Wednesday
0.24%
49.1%
1166
Thursday
0.11%
49.4%
1144
Friday
0.21%
49.6%
1136
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 113.1%
Insider Transactions — Smart Summary
Total insider ownership: 1.1%
Founder-led management: Helen Torley (President, Chief Executive Officer and Member of the Board of Directors)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Halozyme Therapeutics Inc
(HALO) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.